Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality

Hypertension

Volumn 63, Issue 5, 2014, Pages 968-976

  Lin, Jou Wei ^a,b   Chang, Chia Hsuin ^a,b,c   Caffrey, James L ^d   Wu, Li Chiu ^c   Lai, Mei Shu ^a,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiotensin receptor antagonists; Cohort studies; Comparative effectiveness research; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGISTER; TREATMENT DURATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; MORTALITY;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BIPHENYL COMPOUNDS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 84902283158     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02550     Document Type: Article

References (31)

1. Farsang C. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk. Vasc Health Risk Manag. 2011; 7: 605-622.
2. Chobanian AV, Bakris GL, Black H.R., Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572. (Pubitemid 37430158)
3. Dahlöf B., Devereux RB, Julius S, et al Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan intervention for endpoint reduction in hypertension. Hypertension. 1998; 32: 989-997. (Pubitemid 29001425)
4. Nixon RM, Müller E, Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract. 2009; 63: 766-775.
5. Liu PP, Maggioni A, Velazquez EJ Use of valsartan in post-myocardial infarction and heart failure patients. J Renin Angiotensin Aldosterone Syst. 2006; 7(SUPPL. 1):S19-S22.
6. Maggioni AP, Fabbri G. VALIANT (VALsartan In Acute myocardial iNfarcTion) trial. Expert Opin Pharmacother. 2005; 6: 507-512. (Pubitemid 40521086)
7. Demers C, McMurray JJ, Swedberg K, Pfeffer M.A., Granger CB, Olofsson B, McKelvie RS, Ostergren J, Michelson E.L., Johansson PA, Wang D, Yusuf S; CHARM Investigators. Impact of candesartan on nonfatal myo-cardial infarction and cardiovascular death in patients with heart failure. JAMA. 2005; 294: 1794-1798. (Pubitemid 41435112)
8. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clin Ther. 2003; 25: 3044-3064. (Pubitemid 38096144)
9. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch W.E., Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Inves tigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
10. Croom KF, Curran MP, Goa K.L., Perry CM Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004; 64: 999-1028. (Pubitemid 38608479)
11. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J., Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbu-minuria in type 2 diabetes. N Engl J Med. 2011; 364: 907-917.
12. Imai E, Chan JC, Ito S, Yamasaki T., Kobayashi F, Haneda M, Makino H; ORIENT Study Investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a mul-ticentre, randomised, placebo-controlled study. Diabetologia. 2011; 54: 2978-2986.
13. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res. 1993; 2: 121-145.
14. Fabiani ME, Dinh DT, Nassis L, Casley D.J., Johnston CI In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan. Am J Hypertens. 2000; 13: 1005-1013.
15. Meredith PA, Murray LS, McInnes GT Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. J Hum Hypertens. 2010; 24: 525-531.
16. Eklind-Cervenka M., Benson L, Dahlström U, Edner M., Rosenqvist M, Lund LH Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA. 2011; 305: 175-182.
17. Wang L, Zhao JW, Liu B, Shi D., Zou Z, Shi XY Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Am J Cardiovasc Drugs. 2012; 12: 335-344.
18. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke. 2003; 34: 2741-2748. (Pubitemid 37392777)
19. Cooper-DeHoff R.M., Gong Y, Handberg E.M., Bavry AA, Denardo SJ, Bakris GL, Pepine CJ Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010; 304: 61-68.
20. Zhenfeng Z, Huilan S, Junya J., Dong L, Shan L. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2011; 12: 365-374.
21. Xi GL, Cheng JW, Lu GC Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Hypertens. 2008; 21: 546-552.
22. Smith DH, Cramer MJ, Neutel J.M., Hettiarachchi R., Koval S. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit. 2003; 8: 111-117. (Pubitemid 37034566)
23. Michel MC, Foster C, Brunner H.R., Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013; 65: 809-848.
24. Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy-a comparison of the renin angio-tensin blocking agents irbesartan and losartan. Expert Opin Pharmacother. 2010; 11: 521-535.
25. Schrader J, Kulschewski A, Dendorfer A. Inhibition of the renin-angiotensin system and the prevention of stroke. Am J Cardiovasc Drugs. 2007; 7: 25-37. (Pubitemid 46698513)
26. Dahlöf B. Prevention of stroke in patients with hypertension. Am J Cardiol. 2007; 100(3A): 17J-24J.
27. Teo K, Yusuf S, Sleight P., Anderson C, Mookadam F, Ramos B., Hilbrich L, Pogue J, Schumacher H; ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004; 148: 52-61. (Pubitemid 38906646)
28. Desai RJ, Ashton CM, Deswal A, Morgan R.O., Mehta HB, Chen H, Aparasu RR, Johnson ML Comparative effectiveness of individual angio-tensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012; 21: 233-240.
29. Sipahi I, Debanne SM, Rowland D.Y., Simon DI, Fang JC Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010; 11: 627-636.
30. Siragy HM. A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vasc Health Risk Manag. 2011; 7: 297-313.
31. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000; 11: 550-560. (Pubitemid 30660034)